Hans Kobel

This inventor holds 8 USPTO granted patents. Top assignees: Sandoz Gmbh, Novartis Ag. Active years: 1983-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Kobel. Retrieved from https://idiyas.com/inventor/hans-kobel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 292(Granted Patents)

Company Filing History:

Years Active: 1983-2001

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6255100 - Cyclosporin fermentation process (2001-07-03),

2. 5981479 - Cyclosporins (1999-11-09),

3. 5767069 - Cyclosporins (1998-06-16),

4. 4804660 - Ergot cyclic peptide alkaloids having a venotonizing effect, useful for (1989-02-14),

5. 4681880 - Use of thio isosteres of ergot peptide alkaloids as vasaconstrictors (1987-07-21),

6. 4639434 - Novel cyclosporins (1987-01-27),

7. 4542135 - 9'Thia-ergots (1985-09-17),

8. 4384996 - Novel cyclosporins (1983-05-24),

Title: The Innovations of Hans Kobel

Introduction

Hans Kobel is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cyclosporins. With a total of 8 patents to his name, Kobel's work has had a profound impact on medical treatments.

Latest Patents

One of his latest patents involves a cyclosporin fermentation process. This innovation has been found to produce nonimmunosuppressive, cyclophilin-binding cyclosporins that are useful in the treatment and prevention of AIDS and AIDS-related disorders. The cyclosporins developed by Kobel include novel derivatives modified at the 4- and/or 5-positions, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Hans Kobel has worked with prominent companies such as Sandoz GmbH and Novartis AG. His experience in these leading pharmaceutical firms has allowed him to refine his skills and contribute to groundbreaking research in the field.

Collaborations

Kobel has collaborated with esteemed colleagues, including Roland M. Wenger and Pietro Bollinger. These partnerships have further enriched his work and expanded the scope of his innovations.

Conclusion

Hans Kobel's contributions to the field of pharmaceuticals, particularly through his patents on cyclosporins, highlight his role as a significant inventor. His work continues to influence the treatment of critical health issues, demonstrating the importance of innovation in medicine.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]